Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database

Cancer

Volumn 118, Issue 11, 2012, Pages 2944-2951

  Kumar, Anita ^a   Vanderplas, Ann ^b   Lacasce, Ann S ^a,c   Rodriguez, Maria A ^d   Crosby, Allison L ^c   Lepisto, Eva ^e   Czuczman, Myron S ^f   Nademanee, Auayporn ^b   Niland, Joyce ^b   Gordon, Leo I ^g   Millenson, Michael ^h   Zelenetz, Andrew D ⁱ   Friedberg, Jonathan W ^j   Abel, Gregory A ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e National Comprehensive Cancer Network   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

central nervous system prophylaxis; diffuse large B cell lymphoma; health services research; propensity score analysis

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE MARROW DISEASE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPROTECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG EVALUATION; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RECURRENCE; RISK FACTORS; SURVIVAL RATE; VINCRISTINE;

EID: 84861337051     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26588     Document Type: Article

References (27)

1. van Besien K, Chul SH, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998; 91: 1178-1184.
2. Bernstein SH, Unger JM, LeBlanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group. J Clin Oncol. 2009; 27: 114-119.
3. Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002; 13: 1099-1107.
4. Bunn PA, Schein PS, Banks PM, et al. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood. 1976; 47: 3-10.
5. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009; 113: 3896-3902.
6. Litam JP, Cabanillas F, Smith TL, et al. Central nervous system involvement in malignant lymphomas: risk factors and implications for prophylaxis. Blood. 1979; 54: 1249-1257.
7. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007; 18: 149-157.
8. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004; 15: 129-133.
9. Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010; 21: 1046-1052.
10. Bos GMJ, van Putten WLJ, van der Holt B, et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Ann Oncol. 1998; 9: 191-194.
11. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol. 2000; 11: 685-690.
12. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003; 21: 20-27.
13. Fonesca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000; 88: 154-161.
14. Liang R, Chiu E, Loke SL,. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol. 1990; 8: 141-145.
15. National Comprehensive Cancer Network (NCCN) Non Hodgkin's lymphoma Clinical Practice Guidelines in Oncology. Fort Washington, PA: National Comprehensive Cancer Network, Inc.; 2010. Available at:. Accessed December 8, 2010.
16. Cheung CW, Burton C, Smith P, et al. Central nervous systemic chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol. 2005; 131: 193-200.
17. Buckstein R, Lim W, Franssen E, et al. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma. 2003; 44: 955-962.
18. Abramson JS, Hellman M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010; 116: 4283-4290.
19. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003; 102: 4284-4289.
20. Arkenau HT, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007; 18: 541-545.
21. Chua SL, Seymour JF, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2002; 43: 1783-1788.
22. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 346: 235-242.
23. Rosenbaum PR, Rubin DB,. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984; 79: 516-524.
24. Lash TL, Silliman RA,. A comparison of the National Death Index and Social Security Administration databases to ascertain vital status. Epidemiology. 2001; 12: 259-261.
25. Schmitz N, Zeynalova S, Glass B, et al. 112 CNS disease in younger patients (60 years) with aggressive lymphoma treated in trials of the German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT). Paper presented at: American Society of Hematology Conference; December 4-7, 2010; Orlando, Fla.
26. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005; 105: 496-502.
27. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009; 114: 3533-3537.